MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized double blind cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis

摘要

BackgroundMultiple sclerosis (MS) is an inflammatory disease of the central nervous system with a degenerative component, leading to irreversible disability. Mesenchymal stem cells (MSC) have been shown to prevent inflammation and neurodegeneration in animal models of MS, but no large phase II clinical trials have yet assessed the exploratory efficacy of MSC for MS.